株探米国株
英語
エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
___________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report: May 1, 2026
(Date of earliest event reported)
 
BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)
 
Nevada
001-37603
30-1341024
(State or Other Jurisdiction of Incorporation)
(Commission File No.)
(IRS Employer Identification Number)
 
40 Marcus Drive, Melville, New York
    11747
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant's telephone number, including area code: (631) 760-8100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
___
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
___
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
___
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
___
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)

Name of each exchange on which registered
Common Stock, $0.0001 par value
BRTX
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ____
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
(f)
___ On May 1, 2026, the Compensation Committee of the Board of Directors of BioRestorative Therapies, Inc. (the “Company”) approved cash bonuses for the Company’s executive officers for the year ended December 31, 2025, as set forth below in the updated Summary Compensation Table.
Summary Compensation Table
The following Summary Compensation Table sets forth all compensation earned in all capacities during the fiscal years ended December 31, 2025 and 2024 by (i) our principal executive officer, and (ii) our two most highly compensated executive officers, other than our principal executive officer, who were serving as an executive officer as of December 31, 2025 and whose total compensation for the 2025 fiscal year, as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories (i) and (ii) are collectively referred to as the Named Executive Officers):
Name and Principal Position
 
Year
 
 
Salary
 
 
Bonus
 
 
Stock Awards(1)
 
 
Option Awards(1)
 
 
All Other Compensation
 
 
Total
 
Lance Alstodt
 
 
2025
 
 
$
596,666
 
 
$
300,000
 (2)
 
$
-
 
 
$
1,512,500
 
 
$
-
 
 
$
2,409,167
 
Chief Executive Officer
 
 
2024
 
 
$
539,583
 
 
$
275,000
 (3)
 
$
-
 
 
$
500,000
 
 
$
-
 
 
$
1,314,583
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Francisco Silva
 
 
2025
 
 
$
566,666
 
 
$
287,500
 (2)
 
 
-
 
 
$
1,468,750
 
 
 
-
 
 
$
2,322,916
 
VP, Research and Development
 
 
2024
 
 
$
514,583
 
 
$
262,500
 (3)
 
$
-
 
 
$
450,000
 
 
$
-
 
 
$
1,227,083
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Robert Kristal
 
 
2025
 
 
$
343,750
 
 
$
140,000
 (2)
 
$
-
 
 
$
318,000
 
 
$
-
 
 
$
801,750
 
Chief Financial Officer
 
 
2024
 
 
$
293,752
 
 
$
90,000
 (3)
 
$
-
 
 
$
300,000
 
 
$
-
 
 
$
683,752
 
 
(1)
Amounts reflect the aggregate grant date fair value of grants made in the fiscal year computed in accordance with stock-based accounting rules (FASB ASC Topic 718-Stock Compensation). Assumptions used in the calculations of these amounts are included in Note 6 to our consolidated financial statements included in this Annual Report.
(2)
The 2025 Bonus amount represents a discretionary bonus in consideration of 2025 services which is to be paid in 2026.
(3)
The 2024 Bonus amount represents a discretionary bonus in consideration of 2024 services which was paid in 2025.
 



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: May 1, 2026
BIORESTORATIVE THERAPIES, INC.
 
 
 
By:/s/ Robert Kristal
 
Robert Kristal
 
Chief Financial Officer
 
 
 
 
 
 
                    
 
 
 
 
 
 
                    
 
 



0001505497 false US 0001505497 2026-05-01 2026-05-01